Why Kashiv BioSciences’ Gujarat plant expansion could redefine biomanufacturing in India
Kashiv BioSciences raises INR 648 crore to expand its Gujarat biologics facility. Find out what this means for India’s role in global drug manufacturing.
NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
How Agenus is taking aim at cold tumors with Fc-enhanced anti-CTLA-4 therapy
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.
Can Vyriad’s VV169 redefine CAR T therapy with single-dose in vivo delivery?
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.
Is givinostat’s entry into Japan a turning point for DMD care and for JCR Pharmaceuticals’ rare disease strategy?
Find out how Italfarmaco and JCR are bringing the DMD drug givinostat to Japan and what it means for rare disease innovation in Asia.
Gilead Sciences acquires RP-3467 from Repare Therapeutics in $30m synthetic lethality deal
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.
Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA
FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.